Picture of Aravive logo

ARAV — Aravive News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Aravive Inc expected to post a loss of 53  cents a share - Earnings Preview

* Aravive Inc  ARAV.OQ   ARAV.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 4
(estimated). 
    * The Houston Texas-based  company is expected to report  a
229.2% increase in revenue to $842.75 thousand from $256
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aravive Inc is for
a loss
of 53 cents per share. For the same quarter last year, the
company reported a loss of 44 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aravive Inc
is
$22​, above​ its last closing price of $1.37. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -0.60      -0.62     Missed  -3
 Sep. 30 2021  -0.47       -0.46      -0.53     Missed  -14.6
 Jun. 30 2021  -0.38       -0.38      -0.35     Beat    8.9​
 Mar. 31 2021  -0.45       -0.45      -0.44     Beat    2.7
 ​​Dec.        -0.52       -0.52      -0.25     Beat    52.1
 31 2020                                                
 Sep. 30 2020  -0.41       -0.42      -0.66     Missed  -58.7​
 Jun. 30 2020  -0.46       -0.46      -0.32     Beat    30.4
 Mar. 31 2020  -0.35       -0.35      -0.72     Missed  -102.8
 This summary was machine generated May 2 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Aravive

See all news